DUBLIN--(BUSINESS WIRE)--The "Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chemotherapy Induced Nausea and Vomiting development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Chemotherapy Induced Nausea and Vomiting
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Chemotherapy Induced Nausea and Vomiting pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Chemotherapy Induced Nausea and Vomiting Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
- Acacia Pharma Ltd
- Aphios Corp
- Astellas Pharma Inc
- Camurus AB
- Daewoong Pharmaceutical Co Ltd
- Heron Therapeutics Inc
- INSYS Therapeutics Inc
- Kyowa Hakko Kirin Co Ltd
- MannKind Corp
- Medlab Clinical Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/b6774z/chemotherapy?w=4